News & Trends - MedTech & Diagnostics
Health Minister and MTAA champion Indigenous health equity, amplifying the Voice during NAIDOC Week

MedTech & Diagnostics News: The Hon Mark Butler MP, Minister for Health and Aged Care and Medical Technology Association of Australia (MTAA) have pledged their support to the Voice to Parliament referendum, coinciding with NAIDOC Week.
Minister Butler emphasised the crucial need for constitutional recognition of First Nations people in Australia. He highlighted the transformative role that a Voice could play in shaping health policies that directly benefit Aboriginal and Torres Strait Islander communities.
The MTAA’s endorsement is a significant step toward recognising the importance of the Uluru Statement from The Heart, which calls for a constitutionally enshrined Voice to Parliament. This move aims to empower Aboriginal and Torres Strait Islanders by giving them a platform to inform and influence policy decisions that directly impact their health.
Healthcare inequalities have long plagued Indigenous communities, leading to shorter life expectancies, limited access to quality care, and poorer health outcomes. The burden of disease faced by Aboriginal and Torres Strait Islanders is a staggering 2.3 times higher than that of other Australians.
“As a nation, it is imperative that we address this pressing issue and strive for health equity for all,” said MTAA in a statement.
While acknowledging that diverse perspectives exist among its members and employees, the MTAA encourages everyone to take the time to become informed and understand the facts before casting their votes in the forthcoming referendum.
To delve into the significance of the Voice in relation to health equity, industry professionals from the medtech, pharma, and biotech sectors joined the First Nations Health Equity Network for a panel discussion recently. This gathering aimed to foster a deeper understanding of the potential impact of a Voice to Parliament on Aboriginal and Torres Strait Islander health policies.
Health gaps between Indigenous and non-Indigenous Australians have long been a cause for concern. Conditions like rheumatic heart disease, often eradicated in developed countries, persist in Indigenous communities due to systemic poverty and limited access to healthcare.
Shockingly, First Nations children aged 5 to 15 are 55 times more likely to die from rheumatic heart disease than their non-Indigenous counterparts. Indigenous Australians experience a life expectancy that is eight years shorter than non-Indigenous Australians, suffer from kidney failure at seven times the rate, and face suicide rates more than double the national average among young people. While cancer deaths declined overall by 10% last decade across Australia, they actually increased by 12% for Indigenous Australians.
Despite significant investments and well-intentioned efforts, the current approach to Indigenous health has fallen short of the mark. Urgent action is needed, and the endorsement of the Voice to Parliament offers a promising new avenue to address these deep-rooted health disparities.
“I am confident that a Voice to the Parliament and to the health minister will help find better, more effective, practical ways to close the gap and allow Aboriginal and Torres Strait Islanders to live longer, healthier, happier lives,” said Minister Butler.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - Pharmaceuticals

Clinicians shift stance, join calls for PBS subsidy of obesity and weight-loss medicines
Over a third of Australian adults live with obesity, and the National Obesity Strategy estimates the direct and indirect costs […]
MoreNews & Trends - Pharmaceuticals

Astellas secures new indication for prostate cancer drug
Astellas Xtandi (enzalutamide) is now TGA registered for a new indication for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with […]
MoreNews & Trends - MedTech & Diagnostics

Stakeholder calls intensify as government stalls on genetic discrimination ban
Calls have intensified for the federal government to honour its commitment to outlaw genetic discrimination in life insurance, as stakeholders […]
MoreNews & Trends - MedTech & Diagnostics

Pressure mounts to expand home-based therapies in kidney disease: World Kidney Day
As Australia marks World Kidney Day, the stark reality is that one in three adults is at risk of chronic […]
More